JC10 Rec'd PCT/PTO 28 OCT 2005

FORM PTO-1390 (Modified)
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
(REV 12-2004)

			TO THE UNITED STATES	ATTORNEY'S DOCKET NUMBER										
			D OFFICE (DO/EO/US)	065691-0413										
	C	ONCERNING A FILING	G UNDER 35 U.S.C. 371	U.S. APPLIOTION NOT (IPTOOPT SEE 37% F.B. 1.6) Unassitued 99900										
		ONAL APPLICATION NO.	INTERNATIONAL FILING DATE 04/28/2004	PRIORITY DATE CLAIMED 04/28/2003										
TITI	LE OF IN	NVENTION												
	USE OF TYROSINE KINASE INHIBITORS FOR TREATING CEREBRAL ISCHEMIA APPLICANT(S) FOR DO/EO/US													
Jean-Pierre KINET et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:														
1.			This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.											
2.			EQUENT submission of items concerning a fi											
3.		This is an express request to items (5), (6), (9) and (21) ind	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.											
4.		The US has been elected (Art	The US has been elected (Article 31).											
5.	\boxtimes	A copy of the International Ap	plication as filed (35 U.S.C. 371(c)(2))											
		is attached hereto (req	uired only if not communicated by the Intern	ational Bureau).										
			ed by the International Bureau.	•										
		is not required, as the	application was filed in the United States Re	ceiving Office (RO/US)										
6.		An English language translati	on of the International Application as filed (3	5 U.S.C. 371(c)(2)).										
		is attached hereto.												
		-	ubmitted under 35 U.S.C. 154(d)(4).	cle 19 (35 I I S.C. 371(c)(3))										
7.			the International Application under PCT Arti- equired only if not transmitted by the Internat											
		 are attached hereto (required only if not transmitted by the International Bureau). have been communicated by the International Bureau. 												
		have not been made; I	however, the time limit for making such ame	ndments has NOT expired.										
	_	have not been made a												
8.		An English language translati	on of the amendments to the claims under P	PCT Article 19 (35 U.S.C. 371(c)(3)).										
9.			An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).											
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).												
iten	ns 11 to	20 below concern other docu	ument(s) or information included:											
11.	\boxtimes	An Information Disclosure Sta	atement under 37 CFR 1.97 and 1.98.											
12.		An assignment document for	recording. A separate cover sheet in compli	iance with 37 CFR 3.28 and 3.31 is included.										
13.	\boxtimes	A Preliminary Amendment.												
14.	\boxtimes	An Application Data Sheet ur	nder 37 CFR 1.76.											
15.		A substitute specification.												
16.		A power of attorney and/or change of address letter.												
17.	\boxtimes		A Transmittal of Nucleotide Sequence And/Or Amino Acid Sequence Disclosures; Statement to Support Filing and											
			th 37 C.F.R. §1.821-§1.825; Paper Copy of S	Sequence Listing and computer-readable										
		Form (CRF) Diskette.	ation and and and and and an or the or	E4/J\/4\										
i			ed international application under 35 U.S.C. 1											
			language translation of the international appl											
20.	\boxtimes	Other items or information: C	opy of International Search Report (2 pages)).										
FOR	FORM PTO-1390 (Modified)													

JC06 Rec'd PCT/PTC 28 OCT 2005

U.S. APPLICATION NO. (If known, see 37 CFR. 1.5) Unassigned FFF 6 PCT/IB2004/001874							ATTORNEY'S DOCKET NUMBER 065691-0413						
File follow	wing tees	nave bee	!										
_	ational fee			- -		\$300	\$	300.00					
22. 🛛 Examina	ation fee			-									
If International prelir				\$	200.00								
provisions of PC	T Article 3	3(1)-(4)				\$100 \$300							
All other situations \$200													
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the													
USPTO as an International Searching Authority \$100													
International Search	1 кероπ р	repared a	\$400 \$500		500.00								
All other situations				TOTAL OF A	NOVE 04	\$500	\$	500.00					
				TOTAL OF AE	-		\$	1000.00					
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$ for													
each additiona													
Total Sheets	Extra Sh	Sheets Number of each additional 50 or fraction		raction	RATE								
				(round up to a whole number)									
117 - 100 =	17	/50 = 1 hishing the oath or declaration later than 30 months fro			-11 6	x \$250.00	\$ \$	250.00					
Surcharge of \$130.0 claimed priority date			ine earliest	•	0.00								
CLAIMS	1		R FILED	NUMBER EXTRA	F	RATE							
Total Claims		3 - 20 =		0	x \$	50.00	\$	0.00					
		1	-3=	0	x\$	200.00	\$	0.00					
Independent Claims		-			+\$	360.00	\$ \$	0.00					
MULTIPLE DEPEN	- DENT CL												
		LATIONS =	\$	1250.00									
	licant clain iced by 1⁄2.		entity statu	s. See 37 CFR 1.27. Fees	above are	•	\$	625.00					
		JBTOTAL =	\$	625.00									
Processing fee of 1	30.00 for f	urnishing	the Englis	h translation later than 30 r	nonths		\$	0.00					
from the earliest cla													
		NAL FEE =	\$	625.00									
Fee for recording th	ne enclose	d assignr	nent (37 C	FR 1.21(h)). The assignment	ent must b	e e	\$	0.00					
				CFR 3.28, 3.31). 40.00 per			1						
	·····		•			NCLOSED =	\$	625.00	 				
							An	ount to be					
								refunded:					
								charged:					
a. A check	k in the a	mount o	f \$625.00	to cover the above fees	is enclo	sed.			١,				
									•				
			sit Accour sheet is er	nt No. <u>19-0741</u> in the an nclosed.	nount of _		to c	cover the abov	/e tees.				
c. 🛛 The Co	ommissio	ner is	hereby a	authorized to charge a	anv addi	tional fees	which	may be read	uired, or credit anv				
overpay	yment to	Deposit	Account I	No. <u>19-0741</u> . A duplicat	te copy o	f this sheet i	s enclos	sed.	,				
d. Fees ar	re to be c	harge to	a credit o	ard. WARNING: Informated on this form. Provi	ation on	this form ma	y becor	ne public. Cre	edit card				
NOTE: Where a	n annroi	nriate ti	me limit ı	under 37 CFR 1.495 ha	s not be	en met. a p	etition 1	to revive (37	CFR 1.137(a) or (b))				
must be filed an	d grante	d to res	tore the	International Applicati	on to pe	nding statu	§. /	M. 1	•				
SEND ALL CORI	RESPON	IDENCE	TO:	11/	Mysh 101 yel								
SIGNATURE													
							phen B. Maebius						
Custon	ner Num	ber: 22	NAME										
		35,264											
								RATION NUMBER					
			VALIDIA MOMOLIN										

10/555060 JC06 Rec'd PCT/PTO 28 OCT 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ATTORNEY DOCKET NO. 065691-0413

Applicant:

Jean-Pierre KINET et al.

Title:

USE OF TYROSINE KINASE INHIBITORS FOR TREATING

CEREBRAL ISCHEMIA

Appl. No.:

Unassigned

Filing Date: 10/28/2005

Examiner:

Unassigned

Art Unit:

Unassigned

TRANSMITTAL OF NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Enclosed are copies of the Sequence Listing and Statement to Support Filing and Submission in accordance with 37 C.F.R. § 1.821-§1.825. Also enclosed is a diskette containing the Sequence Listing in computer readable form.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Stephen B. Maebius

Attorney for Applicant Registration No. 35,264

October 28, 2005

Date

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone:

(202) 672-5569

Facsimile:

(202) 672-5399